The University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia.
Infectious Diseases Unit, Caboolture Hospital, Caboolture, Queensland, Australia.
Infect Dis (Lond). 2024 Apr;56(4):268-276. doi: 10.1080/23744235.2023.2294122. Epub 2023 Dec 13.
A prompt diagnosis of bacteraemia and sepsis is essential. Markers to predict the risk of persistent bacteraemia and metastatic infection are lacking. SeptiCyte RAPID is a host response assay stratifying patients according to the risk of infectious vs sterile inflammation through a scoring system (SeptiScore). In this study we explore the association between SeptiScore and persistent bacteraemia as well as metastatic and persistent infection in the context of a proven bacteraemia episode.
This is a prospective multicentre observational 14-month study on patients with proven bacteraemia caused by or Gram-negative bacilli. Samples for assessment by SeptiCyte were collected with paired blood cultures for 4 consecutive days after the index blood culture.
We included 86 patients in the study, 40 with and 46 with Gram-negative bacilli bacteraemia. SeptiScores over the follow-up were higher in patients with Gram-negative compared to bacteraemia (median 6.4, IQR 5.5-7.4 vs 5.6 IQR 5.1-6.2, = 0.002). Higher SeptiScores were found to be associated with positive blood cultures at follow-up (AUC = 0.86, 95%CI 0.68-1.00) and with a diagnosis of metastatic infection at day 1 and 2 of follow-up (AUC = 0.79, 95%CI 0.57-1.00 and AUC = 0.82, 95%CI 0.63-1.00 respectively) in the context of Gram-negative bacteraemia while no association between SeptiScore and the outcomes of interest was observed in bacteraemia. Mixed models confirmed the association of SeptiScore with positive blood cultures at follow-up ( = 0.04) and metastatic infection ( = 0.03) in the context of Gram-negative bacteraemia but not bacteraemia after adjusting for confounders.
SeptiScores differ in the follow-up of and Gram-negative bacteraemia. In the setting of Gram-negative bacteraemia SeptiScore demonstrated a good negative predictive value for the outcomes of interest and might help rule out the persistence of infection defined as metastatic spread, lack of source control or persistent bacteraemia.
快速诊断菌血症和脓毒症至关重要。目前缺乏预测持续性菌血症和转移性感染风险的标志物。Sep- tiCyte RAPID 是一种宿主反应检测方法,通过评分系统(Sep- tiScore)将患者分为感染性炎症与无菌性炎症风险。在本研究中,我们探讨了 Sep- tiScore 与持续性菌血症以及在已确诊菌血症情况下的转移性和持续性感染之间的关联。
这是一项前瞻性多中心观察性研究,共纳入 14 个月内由 或革兰氏阴性菌引起的已确诊菌血症患者。在指数血培养后连续 4 天,通过 SeptiCyte 检测采集配对血培养样本。
本研究共纳入 86 例患者,其中 40 例为 菌血症,46 例为革兰氏阴性菌菌血症。与 菌血症相比,革兰氏阴性菌菌血症患者的 Sep- tiScore 在随访期间更高(中位数 6.4,IQR 5.5-7.4 比 5.6 IQR 5.1-6.2, = 0.002)。更高的 Sep- tiScore 与随访时的阳性血培养(AUC = 0.86,95%CI 0.68-1.00)以及革兰氏阴性菌菌血症时第 1 天和第 2 天的转移性感染(AUC = 0.79,95%CI 0.57-1.00 和 AUC = 0.82,95%CI 0.63-1.00)相关,而在 菌血症中,Sep- tiScore 与上述结果均无相关性。混合模型在调整混杂因素后,确认了 Sep- tiScore 与革兰氏阴性菌菌血症时的随访阳性血培养( = 0.04)和转移性感染( = 0.03)相关,但与 菌血症无关。
Sep- tiScore 在 与革兰氏阴性菌菌血症的随访中存在差异。在革兰氏阴性菌菌血症中,Sep- tiScore 对上述结果具有良好的阴性预测值,可能有助于排除转移性感染的持续存在,如无感染源控制或持续性菌血症。